Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Visa to Move European Headquarters to London’s Canary Wharf 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
TUSTIN, Calif., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the second quarter of fiscal year 2016 ended October 31, 2015 on December 10, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the second quarter and review the recent progress of its clinical development programs.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.
To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials focused on the treatment of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of previously treated non-small cell lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.
Contacts: Jay Carlson Peregrine Pharmaceuticals, Inc. (800) 987-8256 [email protected] Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
